Shenzhen Kangtai Biological Products Beheer

Beheer criteriumcontroles 2/4

De CEO Shenzhen Kangtai Biological Products is Xiang Miao, benoemd in Dec2021, heeft een ambtstermijn van 2.92 jaar. bezit rechtstreeks 0.17% van de aandelen van het bedrijf, ter waarde CN¥ 35.88M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 12.2 jaar.

Belangrijke informatie

Xiang Miao

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.9yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	12.2yrs

Recente managementupdates

Recent updates

CEO

Xiang Miao (51 yo)

2.9yrs

Tenure

CN¥3,337,100

Compensatie

Mr. Xiang Miao has been President at Shenzhen Kangtai Biological Products Co., Ltd. since December 29, 2021 and serves as its Director and served as its Vice President and Secretary.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hui Zhou	Chief Financial Officer	2.9yrs	CN¥1.37m	0.012% CN¥ 2.6m
Xiang Miao	President & Non-Independent Director	2.9yrs	CN¥3.34m	0.17% CN¥ 35.9m
Jiankai Liu	VP & Non-Independent Director	2.9yrs	CN¥3.40m	0.16% CN¥ 34.0m
Jin Tao	Board Secretary	2.9yrs	CN¥955.50k	0.014% CN¥ 2.9m

2.9yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300601 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xiang Miao	President & Non-Independent Director	no data	CN¥3.34m	0.17% CN¥ 35.9m
Jiankai Liu	VP & Non-Independent Director	16.2yrs	CN¥3.40m	0.16% CN¥ 34.0m
Weimin Du	Chairman of the Board	16.2yrs	CN¥3.51m	25.5% CN¥ 5.4b
Zhiyun Lu	Chairman of the Supervisory Board	12.2yrs	geen gegevens	0.038% CN¥ 8.0m
Hak Ping Wu	Independent Director	2.9yrs	CN¥112.50k	geen gegevens
Feidong Wen	Vice Chairman	2.9yrs	CN¥2.11m	0.0081% CN¥ 1.7m

12.2yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300601 zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.2 jaar).

Shenzhen Kangtai Biological Products Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.17 in 3Q 2023)

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 27%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.099 (vs CN¥0.28 in 2Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shenzhen Kangtai Biological Products Co., Ltd. Announces Dividend Implementation (Cash Only) Payable on 14 June 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.18 in 1Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 17%

Shenzhen Kangtai Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.074 in 3Q 2022)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemented (A Shares) for 2023, Payable on 13 October 2023

Shenzhen Kangtai Biological Products Co., Ltd. Approves 2023 Interim Cash Dividend

Shenzhen Kangtai Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.14 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.25 in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.64 in 3Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Second quarter 2022 earnings released: CN¥0.53 loss per share (vs CN¥0.28 profit in 2Q 2021)

Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) announces an Equity Buyback for CNY 200 million worth of its shares.

Shenzhen Kangtai Biological Products Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on 2 June 2022

Shenzhen Kangtai Biological Products Co., Ltd. Approves Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.037 in 1Q 2021)

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥1.88 (vs CN¥1.03 in FY 2020)

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.26 in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.39 in 2Q 2020)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Administration Approval to BIOKANGTAI COVID-19 Vaccine for Phase III Clinical Trial in the Philippines

Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independently Developed and Manufactured by Shenzhen Kangtai Biological Products Co., Ltd. is Officially Initiated in Malaysia

Shenzhen Kangtai Biological Products Co., Ltd. Not to Pay Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.004 in 1Q 2020)

New 90-day low: CN¥135

New 90-day high: CN¥181

New 90-day low: CN¥149

Third quarter earnings released

New 90-day low: CN¥157

New 90-day high - CN¥227

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2020 Results on Jul 21, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd